Status:
UNKNOWN
Exhaled Breath Particles as a Clinical Indicator for Lung Injury and Acute Respiratory Distress Syndrome (ARDS)
Lead Sponsor:
Lund University Hospital
Conditions:
Covid19
ARDS, Human
Eligibility:
All Genders
16-90 years
Brief Summary
Acute Respiratory Distress Syndrome (ARDS) reflects the hallmark of the critical course of coronavirus (COVID19). The investigators have recently shown that Exhaled Breath Particles (EBP) measured as ...
Detailed Description
EBP will be measured on 100 patients who are coronavirus (COVID-19) positive as indicated by PCR tests. Measurement will be done on daily basis from the time the patient is admitted to the hospital as...
Eligibility Criteria
Inclusion
- Clinical diagnosis of ALI
- Clinical diagnosis of ARDS
- COVID-19 infection as measured by a positive PCR test
Exclusion
- Dementia
- Severe neurological disease
- Drug abuse
Key Trial Info
Start Date :
May 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 1 2025
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT04503057
Start Date
May 1 2020
End Date
May 1 2025
Last Update
April 12 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Region Skåne
Lund, Skåne County, Sweden, 22460